Abstract The United Kingdom (UK) uveal melanoma guideline development group used an evidence based systematic approach (Scottish Intercollegiate Guidelines Network (SIGN)) to make recommendations in key areas of uncertainty in the field including: the use and effectiveness of new technologies for prognostication, the appropriate pathway for the surveillance of patients following treatment for primary uveal melanoma, the use and effectiveness of new technologies in the treatment of hepatic recurrence and the use of systemic treatments. The guidelines were sent for international peer review and have been accredited by NICE. A http://dx
summary of key recommendations is presented. The full documents are available on the Melanoma Focus website. Ó 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Aim of the guideline
The aim of these guidelines is to optimise patient care by providing recommendations based on the best available scientific evidence. These guidelines should assist the planning of patient care and provide an indication of the likely clinical outcomes, as well as facilitating patient counselling and informed decision-making. Where adequate evidence is lacking, the guideline development group (GDG) has, where possible, arrived at an expert consensus. The Group recognises, however, that each patient is an individual. These guidelines should therefore neither be prescriptive nor dictate clinical care; however, where care significantly differs from the guidelines, it should be justifiable. Our review also identifies gaps in current evidence, thereby defining scope for further research and audit.
The GDG reviewed the evidence, where available, for the key areas of uncertainty in the field, which include:
The use and effectiveness of new technologies such as cytogenetics/genetic analysis for prognostication. The appropriate pathway for the surveillance of patients following treatment for primary uveal melanoma. The use and effectiveness of new technologies in the treatment of hepatic recurrence. The use of systemic treatments.
Background
Uveal melanoma has an incidence of approximately 2-8 per million per year in Caucasians [23] these tumours are even less common in races with brown eyes. More than 90% involve the choroid, the remainder being confined to iris and ciliary body. Both sexes are affected in equal numbers [12, 5] . The age at presentation peaks at approximately 60 years, except for iris melanomas, which usually present at a younger age [5, 18] . Risk factors for uveal melanoma include light-coloured irides [15] , congenital ocular melanocytosis [19] , melanocytoma [14] and neurofibromatosis [19] . The role of sunlight is uncertain [20] . Familial cases are very rare but some patients may have familial atypical mole and melanoma syndrome; these cases require monitoring by a dermatologist as they are also at risk of cutaneous melanoma [22] . Rare families carry germline mutations of the BAP1 gene on chromosome 3, which predisposes them to develop uveal melanoma, mesothelioma and other cancers [2] .
Staging for uveal melanoma follows the American Joint Committee on Cancer (AJCC) Tumour-Node-Metastasis (TNM) staging system for eye cancer [7, 8] . Outcomes for patients with uveal melanoma vary widely, but for patients with early tumours they are excellent. In a cohort of 8033 patients, the 10-year metastatic rate for a 1-mm-thick uveal melanoma was 5%, for a 2-mm-thick uveal melanoma it was 10%, and that for a 6-mm-thick uveal melanoma it was 30% [16, 17] . When grouping 7621 uveal melanomas into small (0-3 mm thick, 29.8%), medium (3.1-8 mm thick, 49%) or large (>8 mm thick, 20.9%) tumours, the 10-year rates of detecting metastases were 11.5%, 25.5% and 49.2% respectively [16, 17] .
An online tool, the Liverpool Uveal Melanoma Prognosticator Online (LUMPO), has been developed and is freely available. It generates an all-cause mortality curve according to age, sex, AJCC TNM size category (based on basal tumour diameter and tumour height), ciliary body involvement, melanoma cytomorphology, closed loops, mitotic count, chromosome 3 loss and presence of extraocular spread (www.ocularmelanomaonline.com) [4] .
Cytogenetic and molecular genetic features of the uveal cells have been demonstrated to have strong prognostication value in uveal melanoma. The most striking abnormality in uveal melanoma is the complete or partial loss of chromosome 3. Other common genetic abnormalities of uveal melanoma include loss on the short arm (p) of chromosome 1, and gains on 6p and 8q (see review, [3] . The above-mentioned chromosomal alterations in primary UM are clinically relevant because of their correlation with the risk of metastatic death. Chromosome 3 loss is associated with a reduction of the 5-year survival probability from approximately 100% to about 50%. Similarly, chromosome 8 gains and loss of chromosome 1 significantly correlate with reduced survival [21, 13] . Conversely, gains in chromosome 6p correlate with a good prognosis, suggesting this aberration may have a functionally protective effect.
The natural history of uveal melanoma is characterised by the frequent development of metastases and patients develop metastatic disease at any time from the initial diagnosis of the primary to several decades later [9, 6, 11] . The risk of metastatic relapse for an individual varies greatly dependent on primary tumour characteristics and genetic alterations.
Outcomes are poor once metastatic disease occurs. The median survival from the time of the development of distant metastatic disease is 2-12 months and 1-year survival 10-15%. This range reflects a number of prognostic factors including the burden of metastatic disease and the effect of metastatic screening programmes [1] .
The liver is the most common site for uveal melanoma metastases, with 50% of patients having liver-only disease, and 90% of those with metastases elsewhere (bowel, bone, lung and lymph nodes) also having liver metastases [10, 24] . Liver disease is usually multifocal, often in a miliary distribution, but some patients may develop isolated metastases, enabling surgical removal. Liver involvement is the cause of death in most patients with metastatic uveal melanoma [24] . Most patients die from parenchymal liver failure, but obstructive jaundice may result from liver metastases compressing the common hepatic or intrahepatic ducts or, less commonly, from porta hepatis nodal disease compressing the extrahepatic duct.
Strengths and limitations of the evidence
Due to the rarity of uveal melanoma and associated poor prognosis, there is limited clinical evidence guiding the optimal treatment of metastatic disease. Most reports in the literature are of small case series of ten or fewer patients. Larger non-randomised studies were scrutinised carefully for a survival bias as mortality is so high. With regard to treatment of primary tumours, each United Kingdom (UK) centre tends to have specific areas of interest and no centre offers all potential treatment options. Whilst the centres compare their results in regular meetings, there are no randomised comparative trials (RCT) from the UK. The COMS study (Collaborative Ocular Melanoma Study (http://www. jhu.edu/wctb/coms/) in the US has provided a valuable source of data; however, overall, the limitations of the evidence base in the literature are considerable.
Risks versus benefits
In weighing up the risks and benefits of any intervention, the guideline development group (GDG) has concentrated on an analysis of clinical benefit and, where appropriate, toxicity. It has not performed any cost-effectiveness analyses as this falls outside the remit of these guidelines.
Methods
The guideline was convened under the UK Melanoma Study Group, a precursor of Melanoma Focus, now a national charity with a professional core membership undertaking research and education in the field of melanoma and skin cancers. The guideline and supporting documentation are available on the Melanoma Focus website http://melanomafocus.com/ activities-2/ocular-melanoma-project/).
The number of health professionals who provide care to patients with uveal melanoma in the UK is relatively small and the aim was to reflect the views of a significant proportion of these within the GDG. There are three ocular oncology referral centres in England that deliver primary treatment (surgery) for patients with uveal melanoma (Liverpool, London and Sheffield) whilst a handful of other centres have a specialist interest in the treatment of uveal melanoma metastatic disease. GDG members were selected to represent these centres as well as the professions involved in delivering care. In addition to the thirteen health professionals, including a trainee, there were originally three patient representatives (one of whom resigned for personal reasons) and a project manager on the GDG. The guideline was started in February of 2012, with the first Guideline Development Group meeting held in April 2012; in all, seven GDG meetings were held over a period of two years. GDG members completed a Declaration of Interest form prior to the first meeting, which was subsequently updated. All interests were declared at the first meeting and it was agreed that members who had a commercial interest in a drug or technology under discussion could remain in the room and answer questions from GDG members but could not participate in the discussion or the formulation of recommendations.
As the clinical area and the associated body of literature is small, it was decided to do one all-encompassing initial literature search and then to sift references for each question within the database. The original search was carried out by the Royal College of Physicians on 27 March 2012, with the search repeated to identify new evidence on 21 June 2013 and again 16 April 2014. Questions were drafted based on inputs from GDG members. Subgroups of content experts on the GDG worked on each topic, agreeing the criteria for including papers, then appraising and extracting references using a 'Scottish Intercollegiate Guidelines Network' (SIGN)) checklist as a guide. However as most of the evidence consisted of small case series, for some questions additional criteria were applied to appraise quality, in particular whether the case series included patients from more than one centre. The sub-groups were supported and advised by a guideline methodologist. The subgroups presented the evidence review and extraction tables to the full GDG at the group's meetings. The full GDG discussed the evidence and formulated evidence statements and recommendations. A great deal of work was done electronically and following update search revisions all GDG members were sent several drafts of chapters for comment.
The evidence was appraised and extracted into tables; see Appendix A, which includes many references that were reviewed but not included in the final document.
A detailed description of the methodology is available in the document entitled Uveal Melanoma Guideline Development Methodology at http://melanomafocus.com/activities-2/the-uveal-melanoma-national-guidelines-project/.
Levels of evidence
The grading of the evidence is based on the Scottish Intercollegiate Guidelines Network (SIGN) grading system 1999-2012 http://www.sign.ac.uk/guidelines/fulltext/50/annexoldb.html.
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias. 1+
Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias. 1À
Meta-analyses, systematic reviews, or RCTs with a high risk of bias. 2++ High quality systematic reviews of case control or cohort or studies. High quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal. 2+
Well-conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal.
1À
Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal. 3
Non-analytic studies, e.g. case reports, case series. 4 Expert opinion.
Grade of recommendations
The grading of recommendations is also based on SIGN 199-2012:
A
At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results. 
